Your search matched 217 results
Pricing Front and Center | In The Media
Leslie Isenegger and Paul Tyahla, Reputation & Risk Management, were featured in the "Pricing Front & Center" article in the January 2018 edition of PharmaVOICE.
Responding to rampant criticism of rising drug prices, pharma giant Eli Lilly will begin selling an authorized generic of its preeminent insulin therapy, Humalog, at half-price.
With a low public tolerance to drug pricing in the recent news, two companies joined forces to help combat the difficult subject when discussing pharmaceutical pricing: transparency.
AVOID THE PRICE CRISIS | In The Media
Meg Alexander, Managing Director of our Reputation & Risk Management Practice, writes about how to avoid the price crisis in this article for PM360.
The industry and the Department of Health and Human Services presented different visions of what greater pricing transparency looks like in the future, complete with separate proposals of how and what information should be shared with consumers.
When Drug Pricing Communications Go Wrong | In The Media
Effective value communications in an era increasingly defined by an increased attention to price.
How could the recent impeachment inquiry effect drug pricing legislation on the Hill?
Pharmaceutical companies across the globe are finding the channels through which they can get desperately needed treatments to patients in need at humane prices.
This month policies aimed at lowering drug prices are back on the table.
Department of Health and Human Services calls for pharmaceutical companies to display drugs’ list prices in their TV commercials.
Rising drug prices have been quite a hot topic this year.
John Seay of our Managed Markets Communications team spoke with PM360 about proposed HHS changes and the impact they will have on rebates and pricing.
COVID-19 Kicks Drug Pricing Down the Road | In The Media
Meg Alexander, head of the reputation and risk management practice at Syneos Health, and Jeff Stewart, managing director at Syneos Health Consulting, teamed up with MM&M to discuss implications of COVID-19 and the upcoming US election on drug pricing.
Drug Pricing Regulatory Action Near Certain | In The Media
Drug pricing regulation is on the horizon and it could affect everything from marketing to pipelines.
Two pharma leaders, Eli Lilly and Johnson & Johnson, have begun disclosing product list prices in their TV commercials, taking the plunge that many brands are still approaching nervously.
Over the past several years, we have all grown accustomed to the drug-pricing-war headlines.
In this collaborative piece, Meg Alexander, Managing Director of our Reputation & Risk Management practice and Susan Suponcic, Managing Director of our Pricing and Market Access practice, highlight misalignments in perception that derail access to orphan drugs.
No, the CEOs of Pfizer and Regeneron are not shaking hands and working it out following their heightened rhetoric about drug prices two years ago.
PUSHBACK ON RARE DRUG PRICES: NOT SO RARE AFTER ALL | In The Media
There’s no doubt the “pricing crisis,” has taken a heavy toll on the reputation of the biopharmaceutical industry.
Instead, we’ve got a look at some of the drug pricing bills that could make it to the floor of the U.S.
Leslie Isenegger, Principal Strategist for Reputation & Risk Management Practice at inVentiv Health Communications, addresses the topic of orphan drug pricing in this article published in Pharmaceutical Executive.
Spent last week watching Shaun White win his third gold medal?
The Week That Was is back in the New Year, with a new look and new company name: Syneos Health.
What impact could the 4 healthcare-related executive orders that President Trump signed last Friday (July 24) have on the pharma industry.
An update on the latest developments in Washington critical to Pharma leaders.
What to Expect on Drug Pricing in the Democratic Trifecta | Perspectives
President Joe Biden hit the ground running, signing 30 executive orders on healthcare.
Fancy a Pharma Chinwag? | Blog
We are gobsmacked at the amount of pharma pricing activity following the release of President Trump’s “Blueprint” to lower drug prices.
In this Pharmafield article, Monique Martin and Doug Niven talk about the gradual but sustained increase in prices of new orphan drugs in Europe.
For a while now activists have been on Pharmaceutical companies to stop gouging prices.